Please use this identifier to cite or link to this item:
Title: Converting an injectable protein therapeutic into an oral form: Phenylalanine ammonia lyase for phenylketonuria
Authors: Kang, T.S. 
Wang, L.
Sarkissian, C.N.
Gámez, A.
Scriver, C.R.
Stevens, R.C.
Keywords: Enzyme substitution therapy
Metabolic disorder
Therapeutic development
Issue Date: Jan-2010
Citation: Kang, T.S., Wang, L., Sarkissian, C.N., Gámez, A., Scriver, C.R., Stevens, R.C. (2010-01). Converting an injectable protein therapeutic into an oral form: Phenylalanine ammonia lyase for phenylketonuria. Molecular Genetics and Metabolism 99 (1) : 4-9. ScholarBank@NUS Repository.
Abstract: Phenylalanine ammonia lyase (PAL) has long been recognized as a potential enzyme replacement therapeutic for treatment of phenylketonuria. However, various strategies for the oral delivery of PAL have been complicated by the low intestinal pH, aggressive proteolytic digestion and circulation time in the GI tract. In this work, we report 3 strategies to address these challenges. First, we used site-directed mutagenesis of a chymotrypsin cleavage site to modestly improve protease resistance; second, we used silica sol-gel material as a matrix to demonstrate that a silica matrix can provide protection to entrapped PAL proteins against intestinal proteases, as well as a low pH of 3.5; finally, we demonstrated that PEGylation of AvPAL surface lysines can reduce the inactivation of the enzyme by trypsin. © 2009 Elsevier Inc. All rights reserved.
Source Title: Molecular Genetics and Metabolism
ISSN: 10967192
DOI: 10.1016/j.ymgme.2009.09.002
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.